Reckitt Benckiser Group (LON:RB) had its target price reduced by investment analysts at Credit Suisse Group from GBX 6,000 ($78.40) to GBX 5,800 ($75.79) in a report released on Tuesday. The firm currently has an “underperform” rating on the stock. Credit Suisse Group’s price objective would indicate a potential downside of 2.60% from the stock’s previous close.
Several other research firms also recently weighed in on RB. Royal Bank of Canada set a GBX 5,100 ($66.64) target price on shares of Reckitt Benckiser Group and gave the stock a “sell” rating in a research report on Wednesday, January 16th. Liberum Capital reissued a “buy” rating and set a GBX 7,600 ($99.31) target price on shares of Reckitt Benckiser Group in a research report on Tuesday, October 30th. UBS Group reaffirmed a “neutral” rating and issued a GBX 6,400 ($83.63) price objective (up from GBX 6,300 ($82.32)) on shares of Reckitt Benckiser Group in a report on Monday, January 14th. Jefferies Financial Group set a GBX 5,000 ($65.33) price objective on shares of Reckitt Benckiser Group and gave the company a “sell” rating in a report on Wednesday, February 6th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Reckitt Benckiser Group in a report on Wednesday, January 30th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company’s stock. Reckitt Benckiser Group has an average rating of “Hold” and a consensus price target of GBX 6,871.67 ($89.79).
LON:RB opened at GBX 5,955 ($77.81) on Tuesday. Reckitt Benckiser Group has a twelve month low of GBX 5,562 ($72.68) and a twelve month high of GBX 8,110.43 ($105.98).
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Further Reading: Trading Options- What is a Strangle?
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.